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ABSTRACT
Introduction: Bisphosphonates inhibit bone resorption by interfering with the action of osteoclasts. Among the adverse 
effects, sclerotic lines observed in the metaphysis of long bones have been described as the main imaging finding in 
pediatric patients. Objective: To evaluate the frequency of radiographic changes caused by alendronate in children and 
adolescents with low bone density or calcinosis. Patients and methods: We conducted a cross-sectional study with 21 
patients who were treated with once-weekly alendronate for at least 10 months. Patients underwent x-rays of long bones 
before the start of alendronate and approximately one year after its use. Results: Eleven patients (52.3%) had sclerotic 
lines in the metaphysis of long bones. The most frequent site was the tibia (8/11 patients), followed by the femur (7/11), 
humerus (6/11), radius (4/11), ulna (3/11), and fibula (2/11). Regression of radiographic changes during the study period 
(up to 1.1 years after discontinuation of alendronate) was not observed. Conclusion: If used carefully, alendronate is 
safe and radiographic changes have not been shown to be clinically relevant.
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INTRODUCTION
Bisphosphonates are synthetic analogues of pyrophosphate that 
bind hydroxyapatite and inhibit bone resorption by interfering 
with the action of osteoclasts.1 Sodium alendronate is a third 
generation bisphosphonate.
Its use in pediatric patients is restricted, as its action on 
skeletal growth has yet to be established and also due to the 
transplacental effects in an eventual pregnancy.2 However, 
some studies have evaluated the efficacy of bisphosphonates 
in children with osteogenesis imperfecta, idiopathic juvenile 
osteoporosis, and secondary osteoporosis, especially 
glucocorticoid (GC)-induced.3-7 The main indications of 
bisphosphonates in childhood include: therapeutic failure 
of the treatment of low bone density for the chronologic age 
(Z score lower than or equal to -2.0 standard deviations); 
intolerance to the conventional treatment with calcium and 
vitamin D; or presence of fractures.8,9 Its beneficial effects 
on bone density gain are well known; however, its long-term 
effects are unknown. Adverse effects, such as abdominal 
pain, diarrhea, nausea, dyspepsia, esophagitis, and exanthema 
have been described. Sclerotic lines in the metaphysis of long 
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bones have been described as the main radiological change 
in pediatric patients or in patients who have growing plates.10
The objective of the present study was to evaluate the 
frequency of radiological changes caused by alendronate in 
children and adolescents with low bone density induced by 
GC or as treatment of calcification of soft tissues (calcinosis).
PATIENTS AND METHODS
A retrospective study was undertaken by obtaining information 
from the medical records of 21 patients with ages between 
8.8 and 22.7 years (mean 16.6 years) from the osteoporosis 
outpatient clinic of the Pediatric Rheumatology Department 
of Universidade Federal de São Paulo. Eighteen patients 
were referred to our service due to low bone mass for their 
chronological age (Z scores lower than or equal to -2.0 standard 
deviations). Additionally, three patients used alendronate due 
to calcinosis associated with juvenile dermatomyositis. All 
patients were on alendronate weekly for at least 10 months 
(35 or 70 mg weekly for weights lower or higher than 30 kg, 
respectively).
METHODS
The bone density of the lumbar spine (L1-L4) was quantified 
through DXA (Dual-energy X-ray absorptiometry) model 
DPX, Lunar. The absolute values were converted in scores of 
standard deviations supplied by the manufacturer.
Patients underwent X-rays of the long bones (humerus, 
radius, ulna, femur, tibia, and fibula) before beginning 
alendronate therapy and approximately one year after its use as 
part of their follow-up routine. The X-rays were analyzed by a 
radiologist observer (AF), who classified the results as absence 
or presence of sclerotic metaphyseal lines in the long bones.
RESULTS
Table 1 shows the demographic characteristics of the patients, 
the age at the diagnosis of low bone density, the time between 
the diagnosis of low bone density and the onset of alendronate, 
the period of use of alendronate, the presence or absence of 
radiological changes, and the location of the sclerotic lines. 
Patients were on alendronate for low bone density (18 patients) 
or calcinosis associated with dermatomyositis/polymyositis 
(three patients). They presented the following diagnoses: 
bronchial asthma (3), intestinal inflammatory disease (3), 
juvenile idiopathic arthritis (2), cystic fibrosis (2), idiopathic 
juvenile osteoporosis (2), allergic rhinitis (1), autoimmune 
hepatitis (1) osteogenesis imperfecta (1), myasthenia gravis 
(1), genetic syndrome (1), and muscular dystrophy (1).
Of the patients included in this study, 71.4% were males 
with age at the time of the evaluation between 9.0 and 22.7 
years (mean of 16.6 years), age at onset of low bone density 
between 5.3 and 17.7 years (mean 12.0 years), and time of 
evolution of low bone density until onset of alendronate 
Table 1
Demographic and clinical data, and 
radiological changes in patients
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1 M 224.1 115.5 67.0 18.2 - —
2 M 249.8 205.1 13.2 12.2 - —
3 M 237.3 180.5 15.2 21.3 + Radius and ulna
4 M 265.8 185.7 30.4 12.2 - —
5 M 127.7 106.4 0.0 12.2 - —
6 M 241.8 108.8 18.3 26.4 - —
7 M 272.6 212.7 0.0 36.5 - —
8 M 136.6 101.0 2.0 20.3 + Tibia
9 F 238.3 171.3 40.6 11.1 - —
10 M 178.9 104.8 13.2 12.2 + Femur and tibia
11 M 272.8 172.4 41.6 17.3 - —
12 F 146.4 63.2 15.2 10.1 + Femur, tibia and humerus
13 M 200.5 143.7 32.4 13.2 + Femur and tibia
14 F 231.5 162.5 21.3 12.2 + Humeru, radius and ulna
15 M 142.6 * * 27.4 + Humerus, radius and ulna
16 F 219.0 175.4 14.2 16.2 - —
17 F 176.6 139.0 3.1 12.2 + Femur, tibia, radius and ulna
18 M 162.7 * * 13.2 - —
19 M 154.4 * * 16.2 + Femur, ulna and humerus
20 M 107.7 81.6 12.2 13.9 +
Femur, tibia, 
fibula and 
humerus
21 F 187.2 165.9 8.1 13.2 + Femur, tibia and fibula
M = male; F = female; TE = Time of evolution. 
*Patients with dermatomyositis/polymyositis and calcinosis.
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between 0.0 and 5.6 years (mean 1.6 years). The duration of 
alendronate ranged from 0.8 to 3.0 years (mean 1.4 years).
Of the patients evaluated, 11 (52.3%) had sclerotic 
metaphyseal lines in the long bones (Figures 1 and 2). The 
most common location was the tibia (8/11), followed by the 
femur (7/11), humerus (6/11), radius (4/11), ulna (3/11), and 
fibula (2/11). The growing plates of one girl and four boys of 
18 years old, who did not present radiological changes at the 
time of onset of alendronate, were closed.
Regression of radiographic changes during the evaluation 
period (up to 1.1 year after alendronate withdrawal) was not 
observed.
DISCUSSION
Osteoporosis is a public health problem with important 
social impact and elevated personal and financial costs.11 
Prevention and treatment of low bone mass secondary to 
rheumatologic diseases in pediatric patients are important to 
obtain an adequate peak of bone mass, therefore preventing 
its consequences in menopause and in the elderly.
A consensus regarding the treatment of low bone mass in 
childhood does not exist. Stimulus for a diet rich in calcium, 
physical activity and sun exposure, use of calcium and vitamin 
D, and the effective control of the underlying disease are 
important.
The use of bisphosphonates in childhood is well established, 
especially the use of pamidronate, in osteogenesis imperfecta 
and idiopathic juvenile osteoporosis.2 Other instances where 
bisphosphonates have been used in a large number of patients 
include osteoporosis secondary to the use of GC in patients 
with systemic diseases and calcinosis.1,12 Some adverse effects 
have been reported, such as nausea, vomiting, abdominal 
pain, esophagitis, uveitis, scleritis, and possible interference 
in bone remodeling of the growing skeletum.2 Regarding the 
linear growth, it has been described that it evolves normally, or 
even more satisfactorily, during treatment with alendronate.13 
However, its long-term effects are unknown. When these 
medications are used before closure of the growing plates, 
sclerotic metaphyseal lines can develop in long bones, without 
any impact on skeletal growth or maturation.14 These lines 
develop at least two months after the onset of the treatment 
and it is believed that they result from the establishment of a 
new balance between osteoblastic and osteoclastic activities, 
i.e., the relative increase in bone formation with high levels 
of osteoblastic activity close to the growing plates would lead 
to the development of sclerotic lines.15 These radiographic 
findings are reversible after discontinuation of the medication, 
although it is not known how long it takes them to disappear 
completely.16 Their long-term meaning is unknown.
In the present study, patients presented varied causes of 
low bone mass and, randomly the male gender predominated.
The presence of sclerotic lines was observed in 50% 
of our patients, which is higher than the results reported in 
the literature. Studies by other authors are limited to case 
Figure 1
Sclerotic metaphyseal lines in the distal femur, and proximal 
tibia and fibula.
Figure 2
Sclerotic metaphyseal lines in distal tibia and fibula.
Silva et al.
290 Bras J Rheumatol 2010;50(3):283-90
reports.1,2,10,14,16 Unal et al. evaluated the efficacy and safety 
of oral alendronate in 22 patients with osteoporosis (11/22 
with connective tissue disease and 13/22 using GC) with ages 
between 4.3 and 19 years (mean 13.3 ± 3.9 years).5 The duration 
of the treatment with alendronate was 14 ± 7.8 months (6 to 
36 months). The authors observed sclerotic lines in 63.6% of 
the patients in knee X-rays (13/22 in metaphysis and 1/22 in 
epiphysis and metaphysis), especially in pre-pubertal patients.5 
In the present study, the duration of the treatment was 0.8 to 3.0 
(mean of 1.4) years. We observed that the presence of sclerotic 
lines was restricted to those patients with growing plates.
Several authors believe that radiological findings are 
reversible after the discontinuation of the drug.1,10,13,16,17 
Fernandes et al. reported the development of sclerotic lines 
in two patients (10 and 14 years of age) on alendronate. The 
authors observed a reduction of sclerotic lines seven months 
after the discontinuation of the drug, without changes in the 
patient's growth rhythm.16 In our population, patients did 
not show regression of sclerotic lines; however, the time of 
evolution after the discontinuation of alendronate was 1.1 
years. The short evolution time and the fact that these patients 
were not at the final phase of growth would be an explanation 
to justify the lack of regression of these changes. Some authors 
described the regression of radiological findings after closure 
of the growing plates.10
Regarding the location of sclerotic lesions, the tibia was 
the most often affected, followed by the femur and humerus. 
Van Persijn et al. observed that knees and elbows were the 
most commonly affected sites.10 The areas that show faster 
growth, such as the distal femur, are usually more commonly 
involved.1,10,14,16
Alendronate is indicated in cases the bone mass does not 
improve, or due to intolerance to conventional therapy with 
calcium and vitamin D, or in the presence of fractures.8 The 
duration of the treatment should not be prolonged, and it should 
be discontinued as soon as therapeutic response is observed. 
Although evidence of accumulation of bone microdamage 
during treatment with bisphosphonates does not exist, this fact 
should always be considered when this therapy in children and 
adolescents is planned. If used with criteria, alendronate is safe 
and, although radiological changes are common in children 
and adolescents, they are not clinically important.
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